-
Newer GLP-1 medications may reduce alcohol-related hospitalization risk
Medical Mythbusting Commentary for July 23, 2026 Source:Newer GLP-1 medications may reduce alcohol-related hospitalization risk Reference:Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
-
Observational study noted that patients with diabetes and obesity using GLP-1 medications may experience reduced degree of metastases. Causality confirmation and mechanisms to be determined.
Medical Mythbusting Commentary for May 25, 2026 Source:GLP-1 Users May Experience A Surprising Life-Saving Benefit That Has Nothing To Do With Weight Loss
-
Unexpected hormone discovery of GLP-1 in joints may provide new avenues for arthritis treatment once it is determined what it is actually doing in the joint. Lots of work ahead.
Medical Mythbusting Commentary for April 30, 2026 Source:Unexpected Hormone Discovery Could Change How We Treat Arthritis Reference:Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis
-
What is the evidence that GLP-1 medications such as Ozempic and Mounjaro might help treat addiction?
Medical Mythbusting Commentary for March 9, 2026 Source:What to know about how GLP-1 medications such as Ozempic and Mounjaro might fight addiction Reference:Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
-
GLP-1 receptor agonist lixisenatide may help slow the progression of Parkinson’s symptoms
Medical Mythbusting Commentary for April 10, 2024 Source:Ozempic-like drug may help slow the progression of Parkinson’s symptoms Reference:Trial of Lixisenatide in Early Parkinson’s Disease